cas 79670-17-0|| where to buy Methyl 5-bromo-2-(bromomethyl)benzoate

製品名:Methyl 5-bromo-2-(bromomethyl)benzoate

IUPAC Name:methyl 5-bromo-2-(bromomethyl)benzoate

包装単位	有効在庫	価格（USD）
CM161997-5g	in stock	Ɠů
CM161997-10g	in stock	ƿŹĲ
CM161997-25g	in stock	ȃǤľ
CM161997-50g	in stock	ŹǤȃ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 79670-17-0 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:79670-17-0; 分子式:C9H8Br2O2; 融点:-; SMILESコード:COC(=O)C1=C(CBr)C=CC(Br)=C1; 密度:

: カタログ番号:CM161997; 分子量:307.97; 沸点:349.7°C at 760 mmHg; MDL番号:; 保管方法:Keep in dark place, inert atmosphere, store at 2-8°C.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: MRT-2359; Aberrant MYC pathway activation is found in cancer cells, while MYC-induced protein translation depends on GSPT1. Molecular glues targeting GSPT1 is identified as a potential treatment method in oncology. Monte Rosa’s MRT-2359 is an oral and selective molecular glue degrader of the translation termination factor GSPT1. The targeted GSPT1 degradation results in disrupting MYC-driven protein translation and reducing MYC-oncogenic signaling.
MRT-2359 is in an ongoing phase 1/2 study in MYC-driven solid tumors with a current assessment of 0.75 mg dose level. The final phase 2 dose determination and updated clinical results are anticipated in the second half of 2024. MRT-2359 previously received Fast Track Designation in patients with previously treated, metastatic NSCLC with L-MYC or N-MYC expression, Orphan Drug Designation in small cell lung cancer (SCLC), and Fast Track Designation in previously treated, metastatic SCLC with L-MYC or N-MYC expression.